Review Report on IL17A Target / Biomarker Content of Review Report on IL17A Target / Biomarker
IL17A
Other Name(s): CTLA8 | interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8) | interleukin-17 | CTLA-8 | Interleukin-17A | Cytotoxic T lymphocyte-associated antigen 8 | IL-17 | ILA17 | IL17_HUMAN | cytotoxic T-lymphocyte-associated protein 8 | Cytotoxic T lymphocyte-associated antigen 8 (CTLA8) | Cytotoxic T-lymphocyte-associated antigen 8 | Interleukin 17A | cytotoxic T-lymphocyte-associated antigen 8 | IL-17A | interleukin 17A | IL17

IL-17A (IL-17) plays critical roles in various immune responses and diseases

In the context of SARS-CoV-2 infection, IL-17A is found to be enriched, leading to a disproportionate immune response and recruitment of innate immune cells, which can result in complications such as ARDS, sepsis, and fibrosis. Furthermore, deficiencies in the IL-17 response pathway can impair cellular responses to IL-17A/F and IL-17A/F production, leading to certain genetic disorders. In psoriasis, IL-17 production by gammadelta T cells contributes to the development of the disease. Additionally, IL-17A is implicated in bone erosion and bone formation in spondyloarthritis. The role of IL-17A in signaling pathways and its interaction with other components, such as NEMO and TBK1/IKKepsilon, is also being studied.
Based on the given context information, here is a summary of key viewpoints related to IL-17A:

IL-17A plays a role in regulating inflammation induced by rhinovirus infections in the upper airways.
IL-17A can inhibit the expression of low-density lipoprotein receptor (LDL-R) and restrict the entry of rhinovirus into airway epithelial cells.
Rhinovirus has the ability to suppress the release of IL-17A, enabling it to evade the immune system.
IL-17A has both tumor-promoting and tumor-protective effects in cancer, with its effects attributed to various molecular signaling pathways and immune cell recruitment.
IL-17A is produced by different immune cell subsets, such as MAIT cells, gammadelta T cells, NKT cells, and ILC3s, and contributes to the pathogenesis of immune-mediated inflammatory diseases like psoriatic arthritis and psoriasis .
IL-17A induces the production of pro-inflammatory cytokines and drives disease progression in psoriatic skin lesions.
IL-17A is involved in the immune response to H. pylori infection, with Th1 and Th17 cells producing proinflammatory cytokines that recruit immune cells to the gastric mucosa.

Overall, IL-17A has diverse roles in regulating inflammation, immune responses, and disease progression in various contexts. Further research is needed to fully understand its mechanisms and potential therapeutic interventions.

Protein Name: Interleukin 17A

Functions: Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity (PubMed:24120361). Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation (PubMed:19825828, PubMed:21350122, PubMed:17911633, PubMed:18684971, PubMed:8676080, PubMed:24120361). Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites (By similarity). In airway epithelium, mediates neutrophil chemotaxis via induction of CXCL1 and CXCL5 chemokines (By similarity). In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells (By similarity). Effector cytokine of a subset of gamma-delta T cells that functions as part of an inflammatory circuit downstream IL1B, TLR2 and IL23A-IL12B to promote neutrophil recruitment for efficient bacterial clearance (By similarity). Effector cytokine of innate immune cells including invariant natural killer cell (iNKT) and group 3 innate lymphoid cells that mediate initial neutrophilic inflammation (By similarity). Involved in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection (PubMed:21350122). Upon acute injury, has a direct role in epithelial barrier formation by regulating OCLN localization and tight junction biogenesis (By similarity). As part of the mucosal immune response induced by commensal bacteria, enhances host's ability to resist pathogenic bacterial and fungal infections by promoting neutrophil recruitment and antimicrobial peptides release (By similarity). In synergy with IL17F, mediates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). Involved in antiviral host defense through various mechanisms (By similarity). Enhances immunity against West Nile virus by promoting T cell cytotoxicity (By similarity). May play a beneficial role in influenza A virus (H5N1) infection by enhancing B cell recruitment and immune response in the lung (By similarity). Contributes to influenza A virus (H1N1) clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense (By similarity)

The "IL17A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL17A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL17B | IL17C | IL17D | IL17F | IL17RA | IL17RB | IL17RC | IL17RD | IL17RE | IL17REL | IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3